Proof of Usefulness Report

Irazu Oncology

Analysis completed on 2/3/2026

+582
Proof of Usefulness Score
Industry Mainstay

Irazu Oncology is a verified, high-potential biotech startup based in the University of Maryland BioPark, led by Dr. Marco Chacón (founder of Paragon Bioservices, sold for $1.2B). The company has secured over $2.6M in seed funding and is developing a novel Outer Membrane Vesicle (OMV) cancer vaccine platform. However, the submission itself is of extremely low quality, containing false claims (e.g., 'most people have used my product', 'reach: everyone') and lacking technical detail. The high score reflects the verifiable off-platform reality of the project's scientific merit, funding, and leadership, despite the poor submission.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+28.5
Audience Reach Impact+4.8
Technical Innovation+16.2
Evidence Of Traction+15.0
Market Timing Relevance+9.0
Functional Completeness+0.25
Subtotal+73.75
Usefulness Multiplierx0.79
Final Score+582

Project Details

Description
Our mission is to develop a superior vaccine platform to improve clinical outcomes for cancer patients.

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Technology choices support scalability goals

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline